<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750007</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20004-Id</org_study_id>
    <nct_id>NCT02750007</nct_id>
  </id_info>
  <brief_title>Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients</brief_title>
  <official_title>Open-label, Non-randomized, Weekly-dose Titration Study to Assess the Tolerability to HS-20004 in Type 2 (Diabetes Mellitus) Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in China. The aim of this trial is to assess the tolerability to
      HS-20004 with titration administration in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events(TEAEs)</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Nausea and vomiting during titration</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Body Weight at different dose steps</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of HS-20004 from baseline at different dose steps</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of glucose from baseline at different dose steps</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of insulin from baseline at different dose steps</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of glucagon from baseline at different dose steps</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients</measure>
    <time_frame>through study completion, an maximum of 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-20004</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes diagnosed for more than 3 months;

          -  HbA1c between ≥6.0 and ≤9.0 %, and FPG between ≥7.0 and ≤13.9 mmol/L;

          -  Body Mass Index (BMI) between 18.5 and 30 kg/m^2 (inclusive) with a total body weight
             of at least 50 kg;

          -  Agree to stop any other drugs for diabetes during washout and study period;

        Exclusion Criteria:

          -  Treatment of GLP-1 analogues, DPP-IV enzyme inhibitors or other analogues before;

          -  History or family history of drug allergy;

          -  Smoker or alcohol abuse;

          -  Currently use or plan to use systemic corticosteroid;

          -  History of recurrent severe hypoglycemia;

          -  History of proliferative retinopathy or maculopathy which required acute treatment;

          -  Impaired hepatic or renal function, or cardiac problem;

          -  Uncontrolled active or untreated hypertension;

          -  Family history of thyroid cancer or submandibular gland cancer, or past history of
             pancreatitis, cholelithiasis, or serious unconscious hypoglycemia history;

          -  Positive of hepatitis B surface antigen, hepatitis C antibody, HIV antibody or
             syphilis antibody;

          -  Subject has participated in any investigational study within 3 months, or is currently
             participating in another clinical study;

          -  Female subject of childbearing potential who does not use an acceptable method of
             birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject
             who does not use an acceptable method of birth control, within six months before
             randomization; Subject who cannot refrain from smoking, eating and/or drinking
             containing xanthine/caffeine, or strenuous exercise, or others that affect drug
             absorption, distribution, metabolism and excretion within 2 days before the study drug
             administration;

          -  Have any other medical abnormality (such as cardiovascular, hepatic, renal,
             gastrointestinal, immunologic, hematological, hormonal, metabolic, neoplasmatic or
             mental disease), which in the opinion of the investigator, might affect the
             absorption, distribution, metabolism, and excretion of the study drug, or prevent the
             patient from following and completing the protocol；

          -  Subject was not used for the study as determined by the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiguang - Zhou</last_name>
    <phone>0731-85292097</phone>
    <email>zhouzg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguang Zhou, Professor</last_name>
      <phone>0731-85292097</phone>
      <email>zhouzg@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

